Aro-Mapt-Sc
Alzheimer Disease, Early Onset
Arrowhead PharmaceuticalsPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
21 Active assets in the Alzheimer Disease, Early Onset cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
RG6289 Banner Health | Phase 2/3 | B |
Donanemab Banner Health | Phase 2/3 | B |
Gnrh Nelly Pitteloud | Phase 2/3 | CCC |
Gonadotropin-Releasing Hormone Nelly Pitteloud | Phase 2/3 | CCC |
PHYSIOLOGIC SODIUM CHLORIDE SOLUTION Nelly Pitteloud | Phase 2/3 | CCC |
View all 26 →
Same molecule, other indications
Aro-Mapt-Sc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →